Q4 2025 Revvity Inc Earnings Call Transcript
Key Points
- Revvity Inc (RVTY) exceeded its adjusted EPS guidance for 2025, achieving $5.06, surpassing initial expectations despite various challenges.
- The company reported a 3% organic growth for the year, aligning with its original guidance range.
- Revvity Inc (RVTY) demonstrated resilience and agility, managing to deliver strong outcomes for customers, employees, and shareholders.
- The diagnostics segment experienced a 7% organic growth in Q4, driven by better-than-expected performance in immunodiagnostics.
- Revvity Inc (RVTY) repurchased over $800 million worth of shares in 2025, reducing its share count by 8.5 million shares, showcasing confidence in its transformation and potential.
- The company faced significant headwinds, including changes in NIH funding, evolving tariffs, and foreign exchange movements.
- Revvity Inc (RVTY) experienced a low single-digit year-over-year decline in sales from academic and government customers.
- The life sciences segment's organic growth was flat year over year, with challenges in the academic and government sectors.
- The adjusted operating margin in Q4 was 29.7%, slightly pressured by reinvestments into the company.
- Revvity Inc (RVTY) anticipates continued challenges in the China diagnostics market due to DRG-related volume pressures.
Ladies and gentlemen, thank you for joining us and welcome to the Q4 2025 Revvity earnings conference call. (Operator Instructions). I will now hand the conference over to Steve Willoughby; SVP, Investor Relations. Steve, please go ahead.
Thank you, operator. Good morning, everyone, and welcome to Revvity's fourth quarter, 2025 earnings conference call. On the call with me today are Prahlad Singh, our President and Chief Executive Officer; and Max Krakowiak, our Senior Vice President and Chief Financial Officer.
I would like to remind you of the Safe Harbor statements in our press release issued earlier this morning in those in our SEC filings.
Statements or comments made on this call may be forward-looking statements, which may include, but may not be limited to financial projections or other statements of the company's plans, objectives, expectations, or intentions.
The company's a result may differ significantly from those projected or suggested due to a
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
